二甲双胍延缓前列腺癌进展的回顾性研究

谭信韬; 刘秋礼; 彭松; 张军; 张尧; 江军

doi:10.16016/j.1000-5404.202101062

您当前的位置：

首页 >

文章列表页 >

二甲双胍延缓前列腺癌进展的回顾性研究

临床医学 | 更新时间：2026-01-09

- 二甲双胍延缓前列腺癌进展的回顾性研究
- Metformin delays progression of prostate cancer: a retrospective study on 192 cases
- 第三军医大学学报 2021年43卷第13期页码：1253-1257
- 作者机构：
  
  400042 重庆，陆军军医大学(第三军医大学)大坪医院泌尿外科
- 作者简介：
  
  [江军，E-mail: jiangjun_64@163.comJIANG Jun, E-mail: jiangjun_64@163.com
- 基金信息：
  
  军队保健专项科研课题(17BJZ13);国家自然科学基金青年科学基金(81802558)
- DOI：10.16016/j.1000-5404.202101062
  中图分类号： R737.25;R969.4;R977.15
- 收稿：2021-01-07，
  
  修回：2021-03-29，
  
  纸质出版：2021-07-15
- 稿件说明：
移动端阅览
谭信韬, 刘秋礼, 彭松, 等. 二甲双胍延缓前列腺癌进展的回顾性研究[J]. 第三军医大学学报, 2021,43(13):1253-1257.

Xintao TAN, Qiuli LIU, Song PENG, et al. Metformin delays progression of prostate cancer: a retrospective study on 192 cases[J]. Journal of Third Military Medical University, 2021, 43(13): 1253-1257.
谭信韬, 刘秋礼, 彭松, 等. 二甲双胍延缓前列腺癌进展的回顾性研究[J]. 第三军医大学学报, 2021,43(13):1253-1257. DOI： 10.16016/j.1000-5404.202101062.

Xintao TAN, Qiuli LIU, Song PENG, et al. Metformin delays progression of prostate cancer: a retrospective study on 192 cases[J]. Journal of Third Military Medical University, 2021, 43(13): 1253-1257. DOI： 10.16016/j.1000-5404.202101062.

摘要

目的

探讨二甲双胍的使用对局限性前列腺癌根治术患者生化复发发生的影响以及骨转移性前列腺癌患者去势治疗抵抗发生的影响。

方法

回顾性分析2008年1月至2020年4月在本科确诊为局限性前列腺癌并行根治性手术且术后发生生化复发的患者31例和骨转移性前列腺癌患者161例，分别分为观察组(二甲双胍±抗雄药物治疗组)和对照组(无处理或单纯抗雄药物治疗组)。分别比较两组患者的基线特征，包括年龄、初始时前列腺特异性抗原(prostate specific antigen，PSA)、生化复发时PSA、病理T分期、Gleason评分。分析两组间生化复发或去势抵抗性前列腺癌(castration-resistant prostate cancer，CRPC)发生时间，前列腺特异性抗原倍增时间(prostate specific antigen double time，PSADT)和PSA最低值的差异。

结果

针对局限性前列腺癌根治术术后生化复发患者，观察组术后无生化复发中位时间(22.73个月)和平均PSADT时间(4.69个月)明显长于对照组术后无生化复发中位时间(10.73个月)和平均PSADT时间(4.30个月)(

0.05)；针对骨转移性前列腺癌患者，观察组的无CRPC发生中位时间(22.35个月)和中位PSADT时间(4.50个月)明显长于对照组的无CRPC发生中位时间(16.05个月)和中位PSADT时间(2.60个月)(

0.05)，两组治疗后PSA最低值差异无统计学意义。

结论

二甲双胍可明显延缓局限性前列腺癌根治术术后生化复发的发生，同时对于转移性前列腺癌可延缓CRPC发生。

Abstract

Objective

To investigate the effects of preoperative use of metformin on the biochemical recurrence (BR) in the patients with localized prostate cancer after radical prostatectomy (RP) and on the occurrence of castration resistance in patients with bone metastasis after RP.

Methods

A retrospective analysis was performed on 192 patients diagnosed with localized prostate cancer and undergoing RP in our hospital from January 2008 to April 2020

including 31 cases of postoperative BR and 161 cases of bone metastatic prostate cancer. The patients were further divided into observation group (metformin with/without androgen deprivation therapy) and control group (no treatment/androgen deprivation therapy alone)

based on whether they were preoperatively treated with metformin or not. The baseline characteristics of the 2 groups were collected and compared

including age

initial prostate specific antigen (PSA) level

PSA level at BR

pathological T stage

and Gleason score. The time to BR or to progression to castration-resistant prostate cancer (CRPC)

PSA doubling time (PSADT)

and PSA minimum were calculated and analyzed between the 2 groups.

Results

For the postoperative BR patients

the median time to BR (22.73

10.73 months

0.05) and mean PSADT (4.69

4.30 months

0.05) were significantly longer in the observation group than the control group. For the patients with bone metastatic prostate cancer

the observation group had obviously longer median time to CRPC (22.35

16.05 months

0.05) and median PSADT (4.50

2.60 months

0.05) when compared with the control gr

oup. But no such difference was seen in PSA minimum after treatment between them.

Conclusion

Metformin can effectively delay the progression of localized prostate cancer to BR after RP

and the progression of bone metastatic prostate cancer to CRPC.

关键词

Keywords

references

CHEAITO K, BAHMAD H F, JALLOUL H, et al . Epidermal growth factor is essential for the maintenance of novel prostate epithelial cells isolated from patient-derived organoids[J ] . Front Cell Dev Biol, 2020, 8: 571677. DOI: 10.3389/fcell.2020.571677.

WANG Y, CHEN J, WU Z, et al . Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it[J ] . Br J Pharmacol, 2021, 178(2): 239-261. DOI:10.1111/bph.15300.

VANCURA A, BU P, BHAGWAT M, et al . Metformin as an anticancer agent[J ] . Trends Pharmacol Sci, 2018, 39(10): 867-878. DOI:10.1016/j.tips.2018.07.006.

HANKINSON S J, FAM M, PATEL N N. A review for clinicians: prostate cancer and the antineoplastic properties of metformin[J]. Urol Oncol, 2017, 35(1): 21-29. DOI:10.1016/j.urolonc.2016.10.009.

BECKMANN K, CRAWLEY D, NORDSTRÖM T, et al . Association between antidiabetic medications and prostate-specific antigen levels and biopsy results[J ] . JAMA Netw Open, 2019, 2(11): e1914689. DOI:10.1001/jamanetworkopen.2019.14689.

LIU Q L, TONG D L, LIU G L, et al . Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-β1/STAT3 axis-regulated EMT[J ] . Cell Death Dis, 2017, 8(8): e3007. DOI:10.1038/cddis.2017.417.

WANG Y, LIU G, TONG D, et al . Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor[J ] . Prostate, 2015, 75(11): 1187-1196. DOI: 10.1002/pros.23000.

CARRION A, INGELMO-TORRES M, LOZANO J J, et al . Prognostic classifier for predicting biochemical recurrence in localized prostate cancer patients after radical prostatectomy[J ] . Urol Oncol, 2020. [Epub ahead of print ] . DOI: 10.1016/j.urolonc.2020.10.075.

王伟, 何家扬. PSADT在前列腺癌患者随访中的价值[J]. 现代泌尿外科杂志, 2008, 13(2): 154-156.

WANG W, HE J Y. The value of PSADT in the follow-up of patients with prostate cancer[J]. J Mod Urol, 2008, 13(2): 154-156.

LV W, SHANG H, PEI X, et al . A simple prognostic model involving prostate-specific antigen, alkaline phosphatase and albumin for predicting the time required to progress to castration-resistant prostate cancer in patients who received androgen deprivation therapy[J ] . Int Urol Nephrol, 2017, 49(1): 61-67. DOI:10.1007/s11255-016-1456-z.

谭信韬, 黄卓韦, 刘秋礼, 等. 前列腺癌骨转移进展为去势抵抗的预测因素分析[J]. 第三军医大学学报, 2021, 43(5): 425-431. DOI:10.16016/j.1000-540.20200908.

TAN X T, HUANG Z W, LIU Q L, et al . Predictive factors for progression to metastatic castration-resistant prostate cancer[J ] . J Third Mil Med Univ, 2021, 43(5): 425-431. DOI:10.16016/j.1000-540.20200908.

SATHIANATHEN N J, OESTREICH M C, BROWN S J, et al . Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer[J ] . Cochrane Database Syst Rev, 2020, 12: C D013245. DOI:10.1002/14651858.CD013245.pub2.

CRABB S J, GRIFFITHS G, MARWOOD E, et al . Pan-AKT inhibitor capivasertib with docetaxel and prednisolone in metastatic castration-resistant prostate cancer: a randomized, placebo-controlled phase Ⅱ trial (ProCAID)[J ] . J Clin Oncol, 2021, 39(3): 190-201. DOI:10.1200/jco.20.01576.

KASZNICKI J, SLIWINSKA A, DRZEWOSKI J. Metformin in cancer prevention and therapy[J]. Ann Transl Med, 2014, 2(6): 57. DOI:10.3978/j.issn.2305-5839.2014.06.01.

SPRATT D E, ZHANG C, ZUMSTEG Z S, et al . Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality[J ] . Eur Urol, 2013, 63(4): 709-716. DOI:10.1016/j.eururo.2012.12.004.

LINKEVICIUTE-ULINSKIENE D, PATASIUS A, KINCIUS M, et al . Preexisting diabetes, metformin use and long-term survival in patients with prostate cancer[J ] . Scand J Urol, 2020, 54(5): 401-407. DOI:10.1080/21681805.2020.1798502.

LI K, SI-TU J, QIU J, et al . Statin and metformin therapy in prostate cancer patients with hyperlipidemia who underwent radiotherapy : a population-based cohort study[J ] . Cancer Manag Res, 2019, 11: 1189-1197. DOI:10.2147/cmar.s166638.

ROTHERMUNDT C, HAYOZ S, TEMPLETON A J, et al . Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09)[J ] . Eur Urol, 2014, 66(3): 468-474. DOI:10.1016/j.eururo.2013.12.057.

JIN D, GUO J, WU Y, et al . Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis[J ] . J Exp Clin Cancer Res, 2020, 39(1): 6. DOI:10.1186/s13046-019-1503-6.

WANG J C, LI G Y, WANG B, et al . Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation[J ] . J Exp Clin Cancer Res, 2019, 38(1): 235. DOI:10.1186/s13046-019-1211-2..

SHARMA P, KUMAR S. Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD)[J ] . Cell Oncol (Dordr), 2018, 41(6): 637-650. DOI:10.1007/s13402-018-0398-0.

LIU Q, YUAN W, TONG D, et al . Metformin represses bladder cancer progression by inhibiting stem cell repopulation via COX2/PGE2/STAT3 axis[J ] . Oncotarget, 2016, 7(19): 28235-28246. DOI:10.18632/oncotarget.8595..

TONG D, LIU Q, LIU G, et al . Metformin inhibits castration-induced EMT in prostate cancer by repressing COX2/PGE2/STAT3 axis[J ] . Cancer Lett, 2017, 389: 23-32. DOI:10.1016/j.canlet.2016.12.031.

GRONICH N, RENNERT G. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates[J]. Nat Rev Clin Oncol, 2013, 10(11): 625-642. DOI:10.1038/nrclinonc.2013.169.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

根治性前列腺癌切除术后首次血清PSA水平的影响因素分析

前列腺癌根治术后生化复发的危险因素分析

二甲双胍抑制IL-6诱导的LNCaP增殖及上皮-间质转化

新型二甲双胍碳点促进炎症微环境下人牙周膜干细胞成骨分化

双氢青蒿素诱导前列腺癌细胞焦亡及调控凋亡相关斑点样蛋白甲基化